Haematology
Inherited Thrombophilia Workup
Indications for testing, panel composition, when NOT to test, anticoagulation duration based on results.
Source: BSH 2010; ISTH
Step 1 of ~3
info
When to Test
Testing indications (BSH):
• Unprovoked VTE in patient <50.
• Recurrent VTE.
• VTE in unusual site (cerebral, splanchnic, hepatic vein).
• VTE in pregnancy / postpartum / on combined OCP / HRT.
• Family history of VTE in first-degree relative + affected by VTE.
• Recurrent miscarriage (≥3) or late fetal loss / placental complications (antiphospholipid).
• Warfarin-induced skin necrosis (protein C/S deficiency).
Do NOT test:
• Routine first VTE in older patient with provoking factor.
• Acute VTE — many tests inaccurate during anticoagulation.
• Without genetic counselling for hereditary thrombophilia.
• Asymptomatic relatives unless clinically indicated.
Related
Curated clinical cross-links plus same-class fallbacks.
Drugs
- Atracurium Besilate · Non-depolarising Neuromuscular Blocking Agent (Intermediate Duration)
- Bivalirudin (PCI Anticoagulation) · Direct Thrombin Inhibitor / PCI
- Dapsone · Anti-inflammatory / Antimicrobial
- Emollient bath and shower products, paraffin-containing · Paraffin-based bath/shower emollient
- Emollient creams and ointments, hydrogenated castor oil-containing · Hydrogenated castor oil-based emollient
- Dimeticone · Topical pediculicide (silicone-based)
Pathways
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only. Always apply local guidelines and clinical judgement.